

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b> 09/653,267	<b>Applicant(s)</b> EINI ET AL.	
	<b>Examiner</b> Mina Haghighatian	<b>Art Unit</b> 1616	

**All Participants:**

(1) Mina Haghighatian.

(2) mary Rose Scozzafava.

**Status of Application:** \_\_\_\_

(3) \_\_\_\_.

(4) \_\_\_\_.

**Date of Interview:** 15 April 2005

**Time:** \_\_\_\_

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

**Exhibit Shown or Demonstrated:** ☐ Yes ☐ No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

Claims discussed:

120-121

Prior art documents discussed:

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

**Part III.**

- ☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

SHELLEY A. DODSON  
PRIMARY EXAMINER

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: Applicant was contacted because in order to place the application in condition for allowance, it was determined that certain biologically active agents listed in claims 120 and 121, such as "a non-nucleoside reverse transcriptase inhibitor", "a nucleoside-analog reverse transcriptase inhibitor" and "a protease inhibitor", were not enabled. Applicant agreed to delete said terms from the claims.